Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Injection of UD NK and TGFBi NK Cells in Cutaneous Keratinocyte Carcinomas
NCT07144384Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of transforming growth factor-beta-imprinted natural killer cells in squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) (2 cohorts), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Change in intratumoral natural killer (NK) cell content at 2 weeks. Started Oct 2025; status: completed.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
squamous cell carcinoma (SCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT07144384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144384.